Tislelizumab extends OS in advanced esophageal cancer

Tislelizumab extended OS compared with chemotherapy for patients with previously treated advanced esophageal squamous cell carcinoma, according to topline data released by the agent’s manufacturer.Tislelizumab (BGB-A317, BeiGene) is humanized immunoglobulin G4 anti-PD-1 monoclonal antibody designed to minimize binding to Fc gamma receptors on macrophages.The randomized phase 3 RATIONALE 302 trial included 512 patients from North America, Europe or Asia with advanced unresectable or metastatic esophageal squamous cell carcinoma who received prior systemic treatment.Researchers assignedRead More

Share on facebook
Share on twitter
Share on linkedin